Trending Now
Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX) Announces $80 Million Underwritten Offering...
Recently, Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a pioneering radiopharmaceutical company specializing in advanced cancer treatments, announced the...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
TapImmune Inc. Common Stock (NASDAQ: MRKR) Announced The Completion Of The...
TapImmune Inc. common stock (NASDAQ: MRKR) made it official that it has recently completed the six-patient safety lead-in portion of the Company's Phase 2...
MAKE IT MODERN
LATEST REVIEWS
The Clinical Study of AT-301 Nasal Spray in the First Group...
When the COVID-19 pandemic first emerged, no one, not even the pharmaceutical industry, was prepared. The world got into a panic mode due to...
MAKE IT MODERN
PERFORMANCE TRAINING
Global Blood Therapeutics Inc. (NASDAQ: GBT) Receives Marketing Approval From the European Commission For...
Global Blood Therapeutics Inc. (NASDAQ: GBT) has announced that the European Commission has given Oxbryta (voxelotor) Marketing Authorization to treat hemolytic anemia resulting from...
Reason why IBRX could reward early traders and investors
ImmunityBio, Inc. (NASDAQ: IBRX) recently made waves in the medical community with its pioneering immunotherapy, ANKTIVA® (nogapendekin alfa inbakicept-pmln), marking a significant...
Agenus (NASDAQ: AGEN) Presents Clinical Data Evaluating AGEN1181 As A Monotherapy or combination with...
Agenus (NASDAQ: AGEN) presented new clinical data for AGEN1181 as a monotherapy and in combination with balstiilimab at the 36th Annual Society of Immunotherapy...
Geneos Therapeutics Inc, a subsidiary of Inovio Pharmaceuticals Inc (NASDAQ: INO), Receives a $17...
Geneos Therapeutics, a subsidiary of Inovio Pharmaceuticals Inc (NASDAQ: INO), has received a Series A2 financing of $17 million. Flerie Invest was in charge...
Omeros Corporation (NASDAQ:OMER) Publishes Final Safety And Efficacy Data From Narsoplimab Stem Cell Transplantation...
Omeros Corporation (NASDAQ:OMER) recently disclosed its comprehensive final findings of its clinical trial evaluating narsoplimab’s performance in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
Narsoplimab...
MAKE IT MODERN
